We are live on ! Find out more
SCM

Squadron Capital Management Portfolio holdings

AUM $322M
This Fund
S&P 500
This Quarter Est. Return
+39.23%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$273M
AUM Growth
+$36.9M
Cap. Flow
+$14.1M
Cap. Flow %
5.18%
Top 10 Hldgs %
67.07%
Holding
52
New
19
Increased
8
Reduced
8
Closed
15

Top Buys

Rank Stock Value
1
ZNTL icon
Zentalis Pharmaceuticals
ZNTL
+$9.38M
2
ANL
Adlai Nortye
ANL
+$8.46M
3
RLMD icon
Relmada Therapeutics
RLMD
+$8.4M
4
NKTR icon
Nektar Therapeutics
NKTR
+$7.12M
5
RLAY icon
Relay Therapeutics
RLAY
+$6.02M

Top Sells

Rank Stock Value
1
MAZE
Maze Therapeutics
MAZE
+$10.3M
2
TERN
Terns Pharmaceuticals
TERN
+$7.68M
3
TARS icon
Tarsus Pharmaceuticals
TARS
+$6.55M
4
UPB
Upstream Bio Inc
UPB
+$6.26M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$4.73M

Sector Composition

Rank Sector Weight
1 Healthcare 91.59%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLYM
51
Climb Bio
CLYM
$938M
– –
-100,000
Closed -$400K
UPB
52
Upstream Bio Inc
UPB
$387M
– –
-230,650
Closed -$6.26M
1 2
3

Similar funds

BCP
Bayberry Capital Partners New York $323M AUM 27.31% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
ECH
ER Collective Holdings Washington, District of Columbia $326M AUM
BCM
Boone Capital Management Atlanta, Georgia $326M AUM 86.31% 1-Year Est. Return
KI
Keewaydin Investments Southampton, New York $317M AUM
GWM
Graybill Wealth Management Elmhurst, Illinois $328M AUM 21.42% 1-Year Est. Return
KC
KHIS Custodian Dallas, Texas $316M AUM
HNH
Hopwood Nicholas Hunter $315M AUM

Squadron Capital Management's Q1 2026 Portfolio in Review

As of Q1 2026, Squadron Capital Management held 52 positions worth $273M, up 16% from $236M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Squadron Capital Management deployed $14.1M of net new capital in Q1 2026, opening 19 new positions and adding to 8 existing holdings. Its largest new stake was Zentalis Pharmaceuticals: 3,631,000 shares worth $8.5M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 95% a quarter earlier.

On the sell side, the largest reduction was Maze Therapeutics, an estimated $10.3M trimmed.

  • Squadron Capital Management's largest Q1 2026 buy was Zentalis Pharmaceuticals: 3,631,000 shares worth $8.5M.
  • Squadron Capital Management added most to Relmada Therapeutics in Q1 2026, an estimated $8.4M increase.
  • Squadron Capital Management's biggest Q1 2026 reduction was Maze Therapeutics, cutting an estimated $10.3M.
  • Squadron Capital Management fully exited Terns Pharmaceuticals in Q1 2026, selling an estimated $7.68M.
  • Squadron Capital Management's ten largest holdings make up 67% of its $273M portfolio in Q1 2026.
  • Squadron Capital Management opened 19 new positions and closed 15 in Q1 2026.
  • Squadron Capital Management's portfolio value rose 16% quarter-over-quarter to $273M.

Based on Squadron Capital Management's 13F filing for Q1 2026, filed 15 May 2026.